Glycomet SR is a next-generation, sustained-release formulation of metformin hydrochloride, specifically engineered to provide prolonged and stable glycemic management in patients with type 2 diabetes. By leveraging a sophisticated drug delivery system, it ensures a gradual release of metformin, minimizing peak-trough fluctuations and enhancing patient compliance. This medication is designed not only to lower blood glucose levels but also to improve insulin sensitivity, making it a cornerstone in modern diabetes therapy. Clinicians favor Glycomet SR for its efficacy, tolerability, and patient-centric pharmacokinetic profile, supporting long-term metabolic health.

Features

• Active ingredient: Metformin hydrochloride (500 mg or 1000 mg per tablet)
• Formulation: Sustained-release (SR) matrix system for controlled drug delivery
• Mechanism: Biguanide class; decreases hepatic glucose production and intestinal absorption, improves insulin sensitivity
• Administration: Oral, once-daily dosing (may be adjusted based on clinical response)
• Bioavailability: Prolonged absorption with reduced Cmax compared to immediate-release formulations
• Excipients: Hydroxypropyl methylcellulose, magnesium stearate, and other pharmacologically inert binders

Benefits

• Provides consistent 24-hour glycemic control with a single daily dose, reducing HbA1c effectively.
• Minimizes gastrointestinal side effects commonly associated with immediate-release metformin, enhancing patient adherence.
• Lowers fasting and postprandial blood glucose levels through dual action on liver and periphery.
• May contribute to modest weight loss or weight neutrality, unlike some other antidiabetic agents.
• Reduces the risk of diabetes-related complications through sustained metabolic management.
• Cost-effective first-line therapy with a well-established safety profile.

Common use

Glycomet SR is primarily indicated for the management of type 2 diabetes mellitus in adults, particularly when lifestyle modifications alone are insufficient. It is often prescribed as monotherapy or in combination with other oral antidiabetic agents or insulin. It may also be used off-label in conditions like polycystic ovary syndrome (PCOS) for improving insulin resistance, under specialist supervision.

Dosage and direction

The usual starting dose is 500 mg once daily, taken with the evening meal. Dosage may be increased gradually, at weekly intervals, based on glycemic response and tolerability, up to a maximum of 2000 mg once daily. Tablets must be swallowed whole; do not crush, chew, or split. Regular monitoring of renal function and blood glucose is advised during therapy. Individualize dosing per patient characteristics and concomitant medications.

Precautions

• Assess renal function before initiation and periodically thereafter; avoid use if eGFR is below 30 mL/min/1.73m².
• Temporarily discontinue during procedures involving iodinated contrast media due to risk of lactic acidosis.
• Use with caution in elderly patients, those with hepatic impairment, or conditions predisposing to hypoxia.
• Monitor vitamin B12 levels annually during long-term therapy due to potential deficiency.
• Inform patients about symptoms of lactic acidosis (e.g., malaise, myalgia, respiratory distress) and advise seeking immediate medical attention if these occur.

Contraindications

• Hypersensitivity to metformin or any component of the formulation.
• Severe renal impairment (eGFR <30 mL/min/1.73m²) or renal disease.
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• Acute conditions predisposing to renal dysfunction, such as dehydration, severe infection, or shock.
• History of lactic acidosis.

Possible side effects

Common side effects (usually transient and dose-related):

• Gastrointestinal: nausea, diarrhea, abdominal discomfort, vomiting, flatulence.
• Metallic taste, decreased appetite.

Less common but serious:

• Lactic acidosis (rare but potentially fatal; symptoms include hyperventilation, myalgia, somnolence).
• Vitamin B12 deficiency with prolonged use.
• Hypoglycemia (especially when used with other glucose-lowering agents).

Drug interaction

• Cimetidine: may increase metformin plasma concentration; monitor and adjust dose if necessary.
• Alcohol: potentiates risk of lactic acidosis; avoid excessive consumption.
• Cationic drugs (e.g., amiloride, digoxin, ranitidine): may interact with metformin elimination.
• Other hypoglycemic agents (e.g., sulfonylureas, insulin): may increase risk of hypoglycemia; dose adjustment may be needed.
• Topiramate: may enhance metformin’s effect on lactate metabolism.

Missed dose

If a dose is missed, take it as soon as remembered on the same day. If it is near the time for the next dose, skip the missed dose and resume the regular schedule. Do not double the dose to make up for a missed one.

Overdose

Overdose may lead to hypoglycemia or lactic acidosis. Symptoms include cold sweats, clammy skin, drowsiness, nausea, and abdominal pain. In case of suspected overdose, seek immediate medical attention. Hypoglycemia should be treated with oral glucose or intravenous dextrose; lactic acidosis may require hemodialysis.

Storage

Store below 30°C, in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for healthcare professionals and educated patients and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations and to address any health concerns or conditions. The prescribing physician should be consulted for dosage adjustments and management of adverse effects.

Reviews

Glycomet SR is widely regarded in clinical practice for its efficacy and improved tolerability. Many endocrinologists note its role in enhancing adherence due to once-daily dosing and reduced gastrointestinal distress. Patients often report better quality of life and stable glucose levels without significant peaks or troughs. Long-term studies support its safety and effectiveness as a foundational therapy in type 2 diabetes management.